Teneligliptin Co-Infusion Alleviates Morphine Tolerance by Inhibition of Spinal Microglial Cell Activation in

Yaswanth Kuthati1, Vaikar Navakanth Rao2, Wei-Hsiu Huang1

  • 1Department of Anesthesiology, Cathy General Hospital, Taipei 106, Taiwan.

Insights

Teneligliptin (TEN) can limit morphine analgesic tolerance (MAT) in diabetic neuropathic pain (DNP) rats. This dipeptidyl peptidase-4 inhibitor (DPP-4i) suppresses microglial activation and restores neuroprotective proteins, offering a potential strategy to improve long-term pain management.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Morphine (MOR) effectively treats moderate to severe diabetic neuropathic pain (DNP) but long-term use is limited by morphine analgesic tolerance (MAT).
  • Microglial cell activation and pro-inflammatory cytokine release are key contributors to MAT development.
  • Dipeptidyl peptidase-4 inhibitors (DPP-4i) like teneligliptin (TEN) are explored for their potential in modulating pain pathways.

Purpose of the Study:

  • To investigate the effects of teneligliptin (TEN) on morphine-induced microglial activation and morphine analgesic tolerance (MAT) in a rat model of diabetic neuropathic pain (DNP).

Main Methods:

  • Diabetic neuropathic pain (DNP) was induced in Wistar rats using streptozotocin (STZ).
  • Rats received intrathecal (i.t.) administration of saline, MOR, TEN, or MOR + TEN for 7 days.
  • Morphine analgesic tolerance (MAT) was assessed via mechanical paw withdrawal and tail-flick tests.
  • Neuroprotective proteins (Nrf2, HO-1) and microglial activation in the spinal cord dorsal horn were evaluated using qPCR, immunofluorescence assay (IFA), and Western blotting (WB).

Main Results:

  • Co-infusion of TEN with MOR significantly attenuated MAT in DNP rats.
  • TEN treatment restored the expression of neuroprotective proteins nuclear factor erythroid 2-related factor (Nrf2) and heme oxygenase-1 (HO-1) in the dorsal horn.
  • TEN suppressed microglial cell activation and mononucleate cell infiltration in the spinal cord dorsal horn.
  • TEN (2 μg) demonstrated mild antinociceptive effects but was highly effective in limiting MAT.

Conclusions:

  • Teneligliptin (TEN) effectively attenuates morphine analgesic tolerance (MAT) in diabetic neuropathic pain (DNP) rats.
  • The mechanism involves the restoration of Nrf2/HO-1 neuroprotective pathways and suppression of spinal microglial activation.
  • TEN represents a promising therapeutic strategy to enhance the long-term efficacy of morphine for DNP management.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
660
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
336
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
186